BRAF and melanoma: The present study demonstrates that inhibitors of the p38 pathway can restore PMCA4b function and reduce migration and metastatic activity of mutant BRAF melanoma cells nearly as efficiently as inhibitors of the BRAF/MEK/ERK pathway, offering a new (additional) mechanism in counteracting (overcoming) resistance to BRAF inhibitors.